Fibromyalgia: alternating magnetic field therapy modestly cuts pain

  • Oka H & al.
  • Pain Med
  • 5 Jun 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Alternating magnetic field therapy (Angel Touch device, AT-02) modestly reduces pain in patients with fibromyalgia in a double-blind randomized, sham-controlled trial.
  • Study design excluded patients with high likelihood of placebo effect.

Why this matters

  • Benefits were comparable in magnitude to that of fibromyalgia drug therapies.

Study design

  • Multicenter, randomized, sham-controlled, double-blind trial of AT-02 vs S-01 (sham alternating magnetic field therapy; n=44).
  • Study began with a 2-week wash-out period of fibromyalgia medications, followed by a 1-week run-in period of S-01 exposure to all subjects. Subjects with ≥30% pain improvement in the run-in period were excluded from randomization (to minimize subsequent placebo effect).
  • Subjects were then randomized to AT-02 or S-01 twice daily for 8 weeks (applied to 4 or more painful sites for 10 minutes at each site).
  • The primary outcome was change in Numeric Rating Scale (NRS)±standard deviation at week 8 vs mean NRS during run-in period.
  • Funding: PEACE OF MIND Co. Ltd.

Key results

  • The AT-02 group had greater reduction in NRS score at 8 weeks vs run-in period (−0.94±1.33 vs −0.22±1.38 in the S-01 group).
    • Findings showed a trend toward a between-group difference (−0.73; P=.0859) and a significant difference in the adjusted repeated measure analysis (−0.72; P=.0386).

Limitations

  • Small sample sizes.